Lastly, although the focus of our study was AML, we suspect that a similar approach with different BH3 mimetics (such as targeting BCL-XL) preceding CTL infusion may demonstrate efficacy in solid tumor models, as the concept of apoptotic priming is conserved among tumor types and solid tumors have been shown to be sensitive to MCL-1 and/or BCL-XL inhibitors [83]. This evidence concerns the gene BCL2L1 and neoplasm.